BMY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT07465029A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in SpainBristol-Myers Squibb · Lower-risk Myelodysplastic Syndromes (TD LR-MDS)Active, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Apr 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04099251Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaBristol-Myers Squibb · MelanomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Jun 28, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin LymphomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc. · Advanced CancerActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05609578Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationMirati Therapeutics Inc. · Advanced NSCLCActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Sep 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07852884First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainBristol-Myers Squibb · Renal Cell Carcinoma (RCC)Active, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Sep 1, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 5, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06122779Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection...Bristol-Myers Squibb · Heart FailureActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07226817A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsBristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 17, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07837115A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of...Celgene · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 19, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.